Improved communication with patients about cost, bleeding, and monitoring may increase compliance
Your search for apixaban returned 100 results
News
Apixaban Seems Safer Than Rivaroxaban for A-Fib
Lower rates seen for ischemic stroke or systemic embolism, GI bleeding or intracranial hemorrhage.
News
Oral Anticoagulants Compared for Gastrointestinal Safety
The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.
News
Labeling for Several HIV Meds Updated to Include Interaction Data With DOACs
If Tybost is given with atazanavir or darunavir, coadministration with rivaroxaban is not recommended due to a potentially increased bleeding risk.
News
Prophylaxis With Apixaban Feasible for Cancer Patients
Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated.
AHA 2015
Apixaban Efficacy, Safety Evaluated in AF Patient on Multiple Concomitant Medications
Older patients, females, and those with comorbidities were more likely to be on multiple medications.
News
Apixaban Beats Aspirin for Stroke Prevention in A-Fib
Apixaban is more effective than aspirin in reducing the risk of repeat stroke and systemic embolism in patients with atrial fibrillation (AF) who are unsuitable for vitamin K antagonists (VKA) therapy.
News
Safety of Direct Oral Anticoagulants Versus Warfarin Investigated
Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.
News
Rates of Recurrent VTE Compared for Apixaban, Rivaroxaban
Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban
